OBSERVATIONAL STUDY OF CHILDREN REQUIRING CRITICAL CARE AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR REFRACTORY/ RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA

被引：0
|
作者：
Ramanathan, G. [1 ]
Gupta, C. [1 ]
Bonney, D. [1 ]
机构：
[1] Royal Manchester Childrens Hosp, Manchester, Lancs, England
来源：
PEDIATRIC CRITICAL CARE MEDICINE | 2022年 / 23卷 / 11期
关键词：
Acute Lymphoblastic Leukemia; Critical Care; immunomodulatory therapy;
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
PP070
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Rheingold, Susan R.
    Ji, Lingyun
    Gore, Lia
    Xu, Xinxin
    Bhojwani, Deepa
    Shah, Nirali N.
    Raetz, Elizabeth A.
    Loh, Mignon L.
    O'Brien, Maureen M.
    BLOOD, 2023, 142
  • [2] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Ceolin, Valeria
    Brivio, Erica
    van Tinteren, Harm
    Rheingold, Susan R.
    Leahy, Allison
    Vormoor, Britta
    O'Brien, Maureen M.
    Rubinstein, Jeremy D.
    Kalwak, Krzysztof
    De Moerloose, Barbara
    Jacoby, Elad
    Bader, Peter
    Lopez-Duarte, Monica
    Goemans, Bianca F.
    Locatelli, Franco
    Hoogerbrugge, Peter
    Calkoen, Friso G.
    Zwaan, Christian Michel
    LEUKEMIA, 2023, 37 (01) : 53 - 60
  • [3] Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Ceolin, Valeria
    Brivio, Erica
    Rheingold, Susan R.
    Leahy, Allison Barz
    Vormoor, Britta Julia
    O'Brien, Maureen M.
    Rubinstein, Jeremy
    Kalwak, Krzysztof
    De Moerloose, Barbara
    Jacoby, Elad
    Bader, Peter
    Fuster, Jose L.
    Locatelli, Franco
    Hoogerbrugge, Peter
    Calkoen, Friso
    Zwaan, Christian M.
    BLOOD, 2021, 138 : 3824 - +
  • [4] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Valeria Ceolin
    Erica Brivio
    Harm van Tinteren
    Susan R. Rheingold
    Allison Leahy
    Britta Vormoor
    Maureen M. O’Brien
    Jeremy D. Rubinstein
    Krzysztof Kalwak
    Barbara De Moerloose
    Elad Jacoby
    Peter Bader
    Mónica López-Duarte
    Bianca F. Goemans
    Franco Locatelli
    Peter Hoogerbrugge
    Friso G. Calkoen
    Christian Michel Zwaan
    Leukemia, 2023, 37 : 53 - 60
  • [5] Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
    Oh, Bernice L. Z.
    Vinanica, Natasha
    Wong, Desmond M. H.
    Campana, Dario
    HAEMATOLOGICA, 2024, 109 (06) : 1677 - 1688
  • [6] CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Retrospective Study
    Zhao, Liping
    Zhou, Qi
    Chen, Chen
    Ling, Zhuojun
    Wang, Kai
    Wu, Fan
    Xu, Jinlong
    Duan, Jiajia
    Wang, Zelin
    Wang, Quangang
    Pan, Jing
    BLOOD, 2023, 142
  • [7] Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Sarkar, Reith
    Gloude, Nicholas Joseph
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
    Lin, John K.
    Lerman, Benjamin J.
    Barnes, James I.
    Boursiquot, Brian C.
    Tan, Yuan Jin
    Robinson, Alex Q. L.
    Davis, Kara L.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3192 - +
  • [9] CAR T-Cell Therapy Pediatric patients with relapsed and refractory acute lymphoblastic leukemia
    Callahan, Colleen
    Baniewicz, Diane
    Ely, Beth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : 22 - 28
  • [10] Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).
    Frey, Noelle V.
    Shaw, Pamela A.
    Hexner, Elizabeth O.
    Gill, Saar
    Marcucci, Katherine
    Luger, Selina M.
    Mangan, James K.
    Grupp, Stephan A.
    Maude, Shannon L.
    Ericson, Solveig
    Levine, Bruce
    Lacey, Simon F.
    Melenhorst, Jan J.
    June, Carl H.
    Porter, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345